Geneva, Nov. 2 -- International Clinical Trials Registry received information related to the study (ChiCTR2600134991) titled 'Tirzepatide Initiated Concomitantly with Olanzapine for the Prevention of Acute Weight Gain: A 4-Week Randomized, Double-Blind, Placebo-Controlled Trial' on Oct. 22.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Peking University Sixth Hospital ( Institute of Mental Health )
Condition:
Acute-phase schizophrenia or schizoaffective disorder in patients initiating olanzapine treatment
Intervention:
Placebo group (P group):0.9% sodium chloride plus olanzapine
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-10-22
Target Sample Size: Placebo group (P ...